Navigation Links
Biannual Antibiotics May Cut Major Cause of Blindness in Africa
Date:2/19/2008

Ocular strain of chlamydia responds well to expanded treatment, report says

TUESDAY, Feb. 19 (HealthDay News) -- Increasing the administration of antibiotics from annually to twice a year in rural African villages could help reduce serious eye infections that can lead to blindness, a new study suggests.

An ocular strain of the sexual transmitted disease chlamydia causes the contagious eye disease trachoma, the leading infectious cause of blindness worldwide. Although it has been eliminated from Western Europe and the United States, it is still common in poor, arid areas such as rural sub-Saharan Africa.

The study, published in the Feb. 20 issue of the Journal of the American Medical Association, showed that giving azithromycin to all residents in eight Ethiopian villages twice a year for two years reduced infection in preschool children 35-fold, from 31.6 percent to 0.9 percent. In eight other villages where only annual doses of the antibiotic were given, researchers found the infection rate in preschool children dropped only sixfold, from 42.6 percent to 6.8 percent at the end of two years.

The prevalence of infection 24 months after the first dose of antibiotics was significantly lower in children in the biannually treated villages (0.9 percent) than in the annually treated villages (6.8 percent). At 24 months, no infection could be identified in preschool children in six of eight of the residents receiving biannual treatment but only in one of eight of the residents receiving annual treatments.

The World Health Organization has launched a program to control trachoma, relying in large part on annual repeated mass azithromycin administrations. Elimination of ocular chlamydia has become a particularly important goal because of a growing concern that infection may return into communities that have lost some of their immunity to chlamydia after antibiotics are discontinued.

Mathematical models have suggested that elimination is possible but may require relatively frequent treatments in regions with high incidence, according to background information in the article.

Biannual coverage of a large portion of the community may be necessary to eliminate infection from a severely affected community or at least to do so in a timely manner. Although programs may be reluctant to devote their scarce resources to more frequent treatment, this may be more cost-effective in the long term. Local elimination of the ocular strains of chlamydia from villages is a feasible goal but may require biannual distributions in hyperendemic areas. The results of this study confirm models that suggest treatments will need to be given for more than the two years to predictably achieve elimination in more than 95 percent of villages. Whether elimination from a larger area is possible will depend on the frequency of community-to-community transmission, the authors concluded.

More information

The U.S. Centers for Disease Control and Prevention has more about chlamydia.



-- Kevin McKeever



SOURCE: Journal of the American Medical Association, news release, Feb. 19, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antibiotics Do Little for Inner Ear Infections
2. DNA with a twist: New company to search for cancer drugs and antibiotics
3. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
4. Antibiotics May Not Help Mens Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives
5. Ear infection superbug discovered to be resistant to all pediatric antibiotics
6. Antibiotics Not Always Best Bet for Battling Childhood Ear Infections
7. Major study links insurance status to advanced stage in multiple cancers
8. Consumer Group Finds Use of Outdated Data and Other Major Flaws in Economists Defense of Mandatory Purchase of Private Health Insurance
9. Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor
10. Good Neighbor Pharmacy(R) Makes Major Gift for Endowed Chair in Community Pharmacy at University of the Pacific
11. Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biannual Antibiotics May Cut Major Cause of Blindness in Africa
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: